skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Ustekinumab (Code C84237)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Ustekinumab

Definition: An orally available, human, IgG1kappa, monoclonal antibody directed against the p40 protein subunit of both interleukin-12 (IL-12) and IL-23, with immunomodulating activity. Upon administration, ustekinumab binds to the p40 subunit of IL-12 and IL-23, blocking the binding of IL-12 and IL-23 to their interleukin receptors. This inhibits IL-12- and IL-23-mediated signaling and inhibits differentiation of CD4 positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent graft versus host disease (GVHD). IL-12 and IL-23, cytokines that play a key role in the regulation of the immune system, are upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD.

Display Name: Ustekinumab

Label: Ustekinumab

NCI Thesaurus Code: C84237 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1608841  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
CNTO 1275
Immunoglobulin G1, Anti-(Human Interleukin-12 Subunit beta (IL-12B, CLMF p40, NKSF2)) (Human Monoclonal CNTO 1275 gamma1-chain), Disulfide with Human Monoclonal CNTO 1275 kappa-chain, Dimer

External Source Codes: 
CAS Registry Number 815610-63-0 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 747205
PDQ Open Trial Search ID 747205 (check for NCI PDQ open clinical trial info)
UMLS CUI C1608841

Other Properties:
     Name Value (qualifiers indented underneath)
code C84237
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom